|Bid||3.07 x 800|
|Ask||3.08 x 3100|
|Day's Range||2.95 - 3.19|
|52 Week Range||1.65 - 5.05|
|Beta (3Y Monthly)||0.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.67|
After earning FDA marketing approval for a controversial new drug, the company is raising cash through a share offering.
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced the pricing of its previously announced underwritten public offering of 12,698,412 shares of its common stock, at a public offering price of $3.15 per share. All of the shares in the offering are to be sold by AcelRx. The offering is expected to close on or about November 14, 2018, subject to the satisfaction of customary closing conditions.
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
REDWOOD CITY, Calif., Nov. 9, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. AcelRx expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. Credit Suisse Securities (USA) LLC, Jefferies LLC, Cantor Fitzgerald & Co. and RBC Capital Markets, LLC are acting as joint book-running managers for the offering.
REDWOOD CITY, Calif. , Nov. 7, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies ...
Critics worried about putting such a potent and addictive medication on the market in the midst of the U.S.’s opioid crisis.
More health care issues are being decided at the ballot box, and Tuesday's election isn't the end of the trend.
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / AcelRx Pharmaceuticals saw big gains this past Friday after announcing third quarter results and an update on DSUVIA receiving FDA approval. Shares of Sage Therapeutics were halted after its treatment Zulresso, was recommended by an FDA approval for postpartum depression. AcelRx Pharmaceuticals, Inc. shares closed up 15.66% on about 20 million shares traded on Friday.
Headed into today’s action following Friday’s mostly uncommitted action, stock charts of Coca-Cola (NYSE:KO), Kinder Morgan (NYSE:KMI) and Adobe (NASDAQ:ADBE) are shaping up as your best trading bets. Coca-Cola shares had been trapped in a trading range as of August, but that range was finally broken this week. • In the weekly timeframe we can see a long-term trading range has also guided Coca-Cola shares upward since 2013.
The Food and Drug Administration on Friday approved a powerful new opioid drug called Dsuvia that has possible uses for treating wounded soldiers on the battlefield. Consumer representatives say the drug is especially potent and particularly susceptible to abuse. Balancing those dangers against needs for powerful painkillers in certain settings has been a dilemma for the FDA amid a national overdose epidemic.
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -5.00% and -65.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Redwood City, California-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks ...
- FDA approved DSUVIA™ for use in adults in a certified medically supervised healthcare setting for the management of acute pain - September 30, 2018 cash, cash equivalents and short-term investments balance ...
Fifteen years after starting the company to prevent dosing errors in medical settings, the company wins its first U.S. regulatory approval.
The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move. The regulator's decision comes as the U.S. opioid crisis reaches epidemic levels, claiming lives of an estimated 130 Americans a day on average, according to the U.S. Centers for Disease Control and Prevention. "There are very tight restrictions being placed on the distribution and use of this product," FDA Commissioner Scott Gottlieb said in a statement.
- DSUVIA (sufentanil sublingual tablet 30 mcg) is indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare ...
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors need to pay close attention to AcelRx Pharmaceuticals (ACRX) stock based on the movements in the options market lately.
A powerful watchdog group says a painkiller more powerful than fentanyl will add to America's opioid crisis; the company says its drug, delivered only in health care settings, provides patients and health care professionals with more options.
As a new medication intended for quick pain relief nears a U.S. approval decision, critics worry about putting another strong opioid on the market amid a devastating opioid crisis.
REDWOOD CITY, Calif. , Oct. 19, 2018 /PRNewswire/ -- In response to opinions expressed following the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee meeting ...
A new, potent opioid medication intended for immediate pain relief has become the center of a maelstrom of controversy as it nears a Food and Drug Administration approval decision early next month. The latest salvo came from Sen. Edward Markey (D-Mass.) on Thursday, calling on the FDA to reject the medication as it is "a thousand times more likely to be abused, and a thousand times more likely to kill." The medication, Dsuvia, is made by the Redwood City, Calif.-based drugmaker AcelRx Pharmaceuticals Inc. , and consists of tablets delivered in an applicator and absorbed beneath the tongue; the company says that the product is intended for moderate-to-severe pain in adults under medical supervision. Dsuvia could help give patients faster and less invasive pain relief than existing options like intramuscular opioid injections, AcelRx says. But critics, including Markey and Public Citizen health researcher Dr. Meena Aladdin, say that the product, which uses an even stronger opioid than the already-potent opioid fentanyl, could pose serious harm and does not offer any real medical benefits over existing options. A FDA advisory committee recommended that the FDA approve Dsuvia last week, in a 10-3 vote. The FDA often follows advisory committee recommendations but is not obligated to do so; a decision is expected by November 3. However, the FDA advisory committee's chair, Dr. Raeford Brown, was not at the committee vote, Markey noted, and Brown has publicly expressed concerns about the product. AcelRx shares declined 1% in Friday morning trade. Shares have surged 39.6% to $4.12 over the last three months, compared with a 0.5% decline in the S&P 500 and a nearly 2% rise in the Dow Jones Industrial Average .